Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of JNJ-64155806 and Ethinylestradiol/Drospirenone
NCT03126097Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AL-794 in influenza, sponsored by Janssen Pharmaceutical. Primary endpoints: Trough Plasma Concentration, Minimum Observed Plasma Concentration and 7 more. Started Apr 2017; status: terminated.
02
Drugs
AL-794
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03126097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126097.